KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Cash: 2009-2025

Historic Change in Cash for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $36.3 million.

  • Biomarin Pharmaceutical's Change in Cash rose 112.23% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $574.7 million, marking a year-over-year increase of 622.58%. This contributed to the annual value of $187.7 million for FY2024, which is 513.53% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Change in Cash of $36.3 million as of Q3 2025, which was down 78.01% from $165.0 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Cash peaked at $267.4 million during Q4 2024, and registered a low of -$296.7 million during Q3 2024.
  • In the last 3 years, Biomarin Pharmaceutical's Change in Cash had a median value of $91.0 million in 2023 and averaged $47.8 million.
  • Its Change in Cash has fluctuated over the past 5 years, first plummeted by 895.29% in 2023, then skyrocketed by 1,403.17% in 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Cash (Quarterly) stood at -$29.9 million in 2021, then declined by 23.83% to -$37.0 million in 2022, then climbed by 18.11% to -$30.3 million in 2023, then surged by 982.87% to $267.4 million in 2024, then skyrocketed by 112.23% to $36.3 million in 2025.
  • Its Change in Cash was $36.3 million in Q3 2025, compared to $165.0 million in Q2 2025 and $106.0 million in Q1 2025.